Company Profile
Oncolys BioPharma provides the research, development, manufacturing, sale, and import of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the United States, and Asia.
Its product pipeline comprises Telomelysin (OBP-301), an oncolytic viral immunotherapy which is in phase II clinical trial to treat gastric cancer. Its portfolio also includes phase I clinical trial for the treatment of HCC, and treatment of esophageal cancer.
It also develops OBP-601(Censavudine), which is in phase II clinical trial to treat progressive supranuclear palsy, amyotrophic lateral sclerosis, and aicardi-goutieres syndrome.
Its portfolio also includes OBP-702, which is in preclinical trial to treat pancreatic cancer, OBP-201, which is in preclinical trial to treat viral infections, and OBP-702 for the treatment of ophthalmology which is in preclinical trial.
Additionally, it develops TelomeScan (OBP-401 and OBP-1101), which is in pilot study trial to treat cancer testing. Incorporated in 2004, the company is headquartered in Minato, Japan.